{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:51:23Z","timestamp":1790970683139,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1016\/j.neurobiolaging.2004.01.006","type":"journal-article","created":{"date-parts":[[2004,3,20]],"date-time":"2004-03-20T12:09:07Z","timestamp":1079784547000},"page":"1283-1292","source":"Crossref","is-referenced-by-count":82,"title":["Aminopyridazines inhibit \u03b2-amyloid-induced glial activation and neuronal damage in vivo"],"prefix":"10.1016","volume":"25","author":[{"given":"Jeffrey M.","family":"Craft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.Martin","family":"Watterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally A.","family":"Frautschy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda J.Van","family":"Eldik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer\u2019s disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-2002-30102","article-title":"Hepatotoxicity of commonly used drugs: non-steroidal anti-inflammatory drugs, anti-hypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs","volume":"22","author":"Chitturi","year":"2002","journal-title":"Semin. Liver Dis"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nn930","article-title":"Exploratory clinical testing of neuroscience drugs","volume":"5","author":"Choi","year":"2002","journal-title":"Nat. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB4","doi-asserted-by":"crossref","first-page":"32046","DOI":"10.1074\/jbc.M201750200","article-title":"Oligomeric and fibrillar species of amyloid-\u03b2 peptides differentially affect neuronal viability","volume":"277","author":"Dahlgren","year":"2002","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB5","first-page":"235","article-title":"Association of an interleukin-1 beta gene polymorphism at position-511 with Alzheimer\u2019s disease","volume":"11","author":"Ehl","year":"2003","journal-title":"Int. J. Mol. Med"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0197-4580(01)00300-1","article-title":"Phenolic anti-inflammatory antioxidant reversal of A\u03b2-induced cognitive deficits and neuropathology","volume":"22","author":"Frautschy","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0197-4580(95)02073-X","article-title":"Rodent models of Alzheimer\u2019s disease: rat A\u03b2 infusion approaches to amyloid deposits","volume":"17","author":"Frautschy","year":"1996","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1750-3639.1998.tb00136.x","article-title":"Glial-neuronal interactions in Alzheimer\u2019s disease: the potential role of a \u201ccytokine cycle\u201d in disease progression","volume":"8","author":"Griffin","year":"1998","journal-title":"Brain Pathol"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB9","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1523\/JNEUROSCI.22-06-02246.2002","article-title":"Microglial activation and \u03b2-amyloid deposit reduction caused by nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice","volume":"22","author":"Jantzen","year":"2002","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB10","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1001\/jama.289.21.2865","article-title":"Nonsteroidal anti-inflammatory drugs and Alzheimer\u2019s disease. What\u2019s next?","volume":"289","author":"Launer","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB11","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Medical progress: drug-induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1523\/JNEUROSCI.23-05-01605.2003","article-title":"Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway","volume":"23","author":"Li","year":"2003","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB13","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1523\/JNEUROSCI.20-15-05709.2000","article-title":"Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer\u2019s disease","volume":"20","author":"Lim","year":"2000","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB14","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543784.11.12.1715","article-title":"Therapies directed at vascular endothelial growth factor","volume":"11","author":"Manley","year":"2002","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/24790","article-title":"Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein","volume":"396","author":"Migaud","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0006-8993(99)01911-3","article-title":"Screening in a cell-based assay for inhibitors of microglial nitric oxide production reveals calmodulin-regulated protein kinases as potential drug discovery targets","volume":"844","author":"Mirzoeva","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/jm015573g","article-title":"Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound","volume":"45","author":"Mirzoeva","year":"2002","journal-title":"J. Med. Chem"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00024382-200116030-00001","article-title":"Role of cerebral inflammation after traumatic brain injury: a revisited concept","volume":"16","author":"Morganti-Kossmann","year":"2001","journal-title":"Shock"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0197-4580(01)00287-1","article-title":"Interleukin-1, neuroinflammation, and Alzheimer\u2019s disease","volume":"22","author":"Mrak","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0197-4580(01)00293-7","article-title":"The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer\u2019s disease","volume":"22","author":"Mrak","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nature01320","article-title":"Points of control in inflammation","volume":"420","author":"Nathan","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0301-0082(02)00127-2","article-title":"An inflammatory review of Parkinson\u2019s disease","volume":"68","author":"Orr","year":"2002","journal-title":"Prog. Neurobiol"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-2002-4510","article-title":"From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer\u2019s disease: the role of NSAIDS and cyclooxygenase in \u03b2-amyloidosis and clinical dementia","volume":"4","author":"Pasinetti","year":"2002","journal-title":"J. Alzheimer Dis"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0197-0186(01)00048-1","article-title":"Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer\u2019s disease","volume":"39","author":"Peskind","year":"2001","journal-title":"Neurochem. Int"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0304-3940(02)01257-0","article-title":"Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer\u2019s disease","volume":"336","author":"Petzold","year":"2003","journal-title":"Neurosci. Lett"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB26","doi-asserted-by":"crossref","first-page":"6421","DOI":"10.1074\/jbc.274.10.6421","article-title":"Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5\u2032-untranslated region sequences","volume":"274","author":"Rogers","year":"1999","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0022-1759(98)00027-1","article-title":"Determination of synapsin I and synaptophysin in body fluid by two-site enzyme-linked immunosorbent assays","volume":"213","author":"Schlaf","year":"1998","journal-title":"J. Immun. Method"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB28","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1359-6446(01)02042-6","article-title":"Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer\u2019s disease","volume":"6","author":"Scorer","year":"2001","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/01.CCM.0000053644.16336.52","article-title":"S-100\u03b2 protein-serum levels in healthy children and its association with outcome in pediatric traumatic brain injury","volume":"31","author":"Spinella","year":"2003","journal-title":"Crit. Care Med"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB30","doi-asserted-by":"crossref","unstructured":"Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752\u2013758.","DOI":"10.1161\/01.STR.30.12.2752"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0167-4889(94)90101-5","article-title":"S100\u03b2 expression in Alzheimer\u2019s disease: relation to neuropathology in brain regions","volume":"1223","author":"Van Eldik","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB32","first-page":"97","article-title":"The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain","volume":"21","author":"Van Eldik","year":"2003","journal-title":"Restor. Neurol. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB33","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1016\/S0960-894X(03)00733-9","article-title":"An aminopyridazine based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia\u2013ischemia\u2013induced brain damage","volume":"13","author":"Velentza","year":"2003","journal-title":"Biorg. Med. Chem. Lett"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB34","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1073\/pnas.1031595100","article-title":"Protein kinase involved in lung injury susceptibility: evidence from enzyme isoform genetic knockout and in vivo inhibitor treatment","volume":"100","author":"Wainwright","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12031-002-0016-4","article-title":"Discovery of new chemical classes of synthetic ligands that suppress neuroinflammatory responses","volume":"19","author":"Watterson","year":"2002","journal-title":"J. Molecul. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2004.01.006_BIB36","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/jhet.5570350508","article-title":"Search for new lead compounds: the example of the chemical and pharmacological dissection of aminopyridazines","volume":"35","author":"Wermuth","year":"1998","journal-title":"J. Heterocyclic Chem"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458004000442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458004000442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T09:23:20Z","timestamp":1550136200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458004000442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["S0197458004000442"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2004.01.006","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}